Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s notice to 340B covered entities on the Office of Pharmacy Affairs website yesterday. The company said its revised 340B ceiling prices are due to revised pricing data submitted to the Centers for Medicare & Medicaid Services.
Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
